Lung structure and function in COPD

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 5, 2008, Pages 467-479

  Hogg, James C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Airway obstruction; Chronic bronchitis; Emphysema; Exacerbations; Pulmonary hypertension

Indexed keywords

ADAPTIVE IMMUNITY; AIRWAY OBSTRUCTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG FUNCTION; LUNG LESION; LUNG STRUCTURE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SMALL AIRWAY DISEASE;

AIRWAY OBSTRUCTION; BRONCHIOLITIS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; IMMUNITY, MUCOSAL; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SMOKING;

EID: 43949136459     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
2. Rabe K F, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
3. Chapman R S, He X, Blair A E, Lan Q. Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study. BMJ 2005; 331: 1050.
4. Ekici A, Ekici M, Kurtipek E, Akin A, et al. Obstructive airway diseases in women exposed to biomass smoke. Environ Res 2005; 99: 93-98.
5. Hnizdo E, Sullivan P A, Bang K M, Wagner G. Airflow obstruction attributable to work in industry and occupation among US race/ethnic groups: a study of NHANES III data. Am J Ind Med 2004; 46: 126-135.
6. Winchester J W. Regional anomalies in chronic obstructive pulmonary disease; comparison with acid air pollution particulate characteristics. Arch Environ Contam Toxicol 1989; 18: 291-306.
7. Mullen J B, Wright J L, Wiggs B R, Pare P D, Hogg J C. Reassessment of inflammation of airways in chronic bronchitis. Br Med J (Clin Res Ed) 1985; 291: 1235-1239.
8. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306.
9. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-1652.
10. Saetta M, Turato G, Facchini F M, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
11. Kemeny D M, Vyas B, Vukmanovic-Stejic M, et al. Cd8(+) T cell subsets and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160 (Suppl): S33-S37.
12. Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 629-626.
13. 1. Am J Respir Crit Care Med 1997; 155: 852-857.
14. Wright J L, Lawson L M, Paré P D, Kennedy S, Wiggs B, Hogg J C The detection of small airways disease. Am Rev Respir Dis 1984; 129: 989-994.
15. Hogg J C, Wright J L, Wiggs B R, Coxson H O, Opazo Saez A, Paré P D. Lung structure and function in cigarette smokers. Thorax 1994; 49: 473-478.
16. Hogg J C, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
17. Retamales I, Elliott W M, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
18. Wright J L, Lawson L M, Pare P D, et al. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis 1983; 127: 474-477.
19. Rutgers S R, Postma D S, ten Haken N H, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
20. Reid L. Measurement of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax 1960; 15: 132-141.
21. McLean K H. The histology of generalized pulmonary emphysema. I. The genesis of the early centrolobular lesion: focal emphysema. Australas Ann Med 1957; 6: 124-140.
22. McLean K H. The histology of generalized pulmonary emphysema. II. Diffuse emphysema. Australas Ann Med 1957; 6: 203-217.
23. Leopold J G, Gough J. Centrilobular form of hypertrophic emphysema and its relation to chronic bronchitis. Thorax 1957; 12: 219-235.
24. McLean K H. The pathogenesis of pulmonary emphysema. Am J Med 1958; 25: 62-74.
25. Wright J L, Lawson L, Pare P D, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. Am Rev Respir Disease 1983; 128: 702-707.
26. Barbera J A, Peinado V I, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
27. Wright J L, Petty T L, Thurlbeck W M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health Nocturnal Oxygen Therapy Trial. Lung 1992; 170: 109-124.
28. Mukae H, Hogg J C, English D, Vincent R, van Eeden S F. Phagocytosis of particulate matter air pollutants (PM1O) by human alveolar macrophages stimulates the bone marrow. Am J Physiol (Lung Mol Biol) 2000; 279: L924-L931.
29. Fujii T, Hayashi S, Hogg J C, Vincent R, van Eeden S. Particulate matter induces cytokine expression in human bronchial epithelial cells. Am J Respir Cell Biol Med 2001; 25: 1-7.
30. Fujii T, Hayashi S, Hogg J C, et al. Interaction of alveolar macrophages and airway epithelial cells following exposure to particulate matter produces mediators that stimulate the bone marrow. Am J Respir Cell Mol Biol 2002; 27: 34-41.
31. Tan W C, Qui D, Liam B L, et al. The human bone marrow response to fine particulate air pollution. Am J Respir Crit Care Med 2000; 161: 1213-1217.
32. 10). Am J Respir Crit Care Med 2001; 164: 826-830.
33. Sakai M, Sato Y, Sato S, et al. Effect of relocating to areas of reduced atmospheric particulate matter levels on the human circulating leukocyte count. J Appl Physiol 2004; 97: 1774-1780.
34. van Eeden S F, Hogg J C. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000; 15: 915-921.
35. Chan-Yeung M, Abboud R, Buncio A D, Vidal S. Peripheral leukocyte count and longitudinal decline in lung function. Thorax 1988; 43: 462-466.
36. 1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol 1995; 142: 493-498.
37. Suwa T, Hogg J C, Quinlan K B, Ohgami A, Vincent R, van Eeden S F. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002; 39: 935-942.
38. Woolcock A J, Vincent N J, Macklem P T. Frequency dependence of compliance as a test for obstruction in the small airways. J Clin Invest 1969; 48: 1097-1106.
39. O'Donnell D E, Webb K A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyper-inflation. Am Rev Respir Dis 1993; 148: 1351-1357.
40. O'Donnell D E. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 180-184. Review.
41. Abbas A K, Lichtman A H, Pillai S. Innate immunity. In: Cellular and molecular immunology. 6th ed. Philadelphia, PA, USA: Saunders Elsevier, 2006; pp 19-46.
42. Simani A S, Inoue S, Hogg J C. Penetration of the respiratory epithelium of guinea pigs following exposure to cigarette smoke. Lab Invest 1974; 31: 75-81.
43. Hulbert W C, Walker D C, Jackson A, Hogg J C. Airway permeability to horseradish peroxidase in guinea pigs: the repair phase after injury by cigarette smoke. Am Rev Respir Dis 1981; 123: 320-326.
44. Jones J G, Minty B D, Lawler P, Hulands G, Crawley J C, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; 1: 66-68.
45. Knowles M R, Boucher R C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002; 109: 571-577.
46. Drannic A G, Pouladi M A, Robbins C S, et al. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2004; 170: 1164-1171.
47. Fels A O, Cohn Z A. The alveolar macrophage. J Appl Physiol 1986; 60: 353-369. Review.
48. Macklin C C. Pulmonary sumps, dust accumulation, alveolar fluid and lymph vessels. Acta Anatomica 1955; 23: 1-33.
49. Niewoehner D E, Kleinerman J, Rice D P. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291: 755-758.
50. Saetta M, Turato G, Facchini F M, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
51. Aoshiba K, Koinuma M, Yokohori N, Nagai A. Differences in the distribution of CD4+ and CD8+ T cells in emphysematous lungs. Respiration 2004; 71: 184-190.
52. Cosio M G, Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002; 121 (Suppl): 160S-165S.
53. Bosken C H, Hards J, Gatter K, Hogg J C. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis 1992; 145: 911-917.
54. Buzatu L, Chu F, Javadifard A, et al. The accumulation of dendritic and natural killer cells in the small airways at different levels of COPD severity [Abstract]. Proc Am Thoracic Soc 2005; 2: A135.
55. Clark-Lewis I, Mattioli I, Gogo J H, Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003; 278: 289-295.
56. Proudfoot A E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115.
57. Lukacs N W. Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy 2004; 4: 313-317.
58. Traves S L, Culpitt S V, Russell R E, Barnes P J, Donnelly L E. Increased levels of the chemokines GRO-α and MCP-1 in sputum samples from patients with COPD. Thorax 2002; 57: 590-595.
59. Morrison D, Strieter R M, Donnelly S C, Burdick M D, Kunkel S L, MacNee W. Neutrophil chemokines in broncho-alveolar lavage fluid and leukocyte-conditioned medium from nonsmokers and smokers. Eur Respir J 1998; 12: 1067-1072.
60. Becker S, Soukup J M, Gilmour M I, Devlin R B. Stimulation of human and rat alveolar macrophages by urban air particulates: effects on oxidant radical generation and cytokine production. Toxicol Appl Pharmacol 1996; 141: 637-648.
61. Quay J L, Reed W, Samet J, Devlin R B. Air pollution particles induce IL-6 gene expression in human airway epithelial cells via NF-kappaB activation. Am J Respir Cell Mol Biol 1998; 19: 98-106.
62. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.
63. Keatings V M, Collins P D, Scott D M, Barnes P J. Differences in interleukin-8 and tumour necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
64. Seatta M. Increased expression of CXCR3 and its Ligand CXCL-10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409.
65. Richmond I, Prichard G E, Ashcroft P A, Walters E H. Bronchial associated lymphoid tissue. Thorax 1993; 48: 1130-1134.
66. Nagaishi C, Nagasawa N, Yamashita M, Okada Y, Inaba N. The lymphoid tissue of the lung. In: Functional anatomy and histology of the lung. Baltimore, MD, USA: University Park Press, 1972: pp 102-179.
67. Pabst R G, Gehrke I. Is the bronchus associated lymphoid tissue (BALT) an integral structure in the lungs of normal mammals, including humans? Am J Respir Cell Mol Biol 1990; 3: 131-135.
68. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 2003; 58: 832-834.
69. Voelkel N, Taraseviciene-Stewart L. Emphysema: an autoimmune disease? Proc Am Thorac Soc 2005; 2: 23-25.
70. Lee S H, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
71. Corr S C, Gahan C C, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 2008; 52: 2-12.
72. Abbas A K, Lichtman A H, Pober J S. Activation of T lymphocytes. In: Cellular and molecular immunology. Philadelphia PA, USA: W B Saunders, 2000: pp 161-181.
73. Abbas, A K, Lichtman A H, Pober J S. B cell activation and antibody production. In: Cellular and molecular immunology. Philadelphia, PA, USA: W B Saunders, 2000: pp 182-207.
74. Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; i: 775-779.
75. Fletcher C, Peto R, Tinker C, Speizer F E. The natural history of chronic bronchitis and emphysema. Oxford, UK: Oxford University Press, 1976.
76. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332.
77. 1 decline and COPD morbidity. Am J Respir Crit Care Med 1996; 153: 1530-1535.
78. Hogg J C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721.
79. Hogg J C, Macklem P T, Thurlbeck W M. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
80. van Brabandt H, Cauberghs M, Verbeken E, Moerman P, Lauweryns J M, Van de Woestijne K P. Partitioning of pulmonary impedance in excised human and canine lungs. J Appl Physiol 1983; 55: 1733-1742.
81. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992; 72: 1016-1023.
82. Matsuba K, Thurlbeck W M. The number and dimensions of small airways in emphysematous lungs. Am J Pathol 1972; 67: 265-275.
83. Mead J, Turner J M, Macklem P T, Little J. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol 1967; 22: 951-958.
84. Laënnec R T H. A treatise on diseases of the chest and on mediate auscultation. Translated by Forbes J. 4th ed. London, UK: Longmans, 1834.
85. McCallum W G. Types of injury: destruction of the respiratory tract. In: A textbook of pathology. 7th ed. Philadelphia, PA, USA: W B Saunders, 1940: pp 419-428.
86. Gross P, Babyuk M A, Toller E, Kashak M. Enzymatically produced pulmonary emphysema. J Occup Med 1964; 6: 481-484.
87. Laurel C B, Erickson S. The electrophoretic alpha-1 globulin pattern of serum α-1 anti-trypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-140.
88. Gadek J E, Fells J A, Crystal R G. Cigarette smoke induces a functional anti-protease deficiency in the lower respiratory tract. Science 1979; 206: 315-316.
89. Ciba Guest Symposium Report. Terminology, definitions and classifications of chronic pulmonary emphysema and related conditions. Thorax 1959; 14: 286-299.
90. The definition of emphysema. Report of a National Heart, Lung and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 1985; 132: 182-185. [No authors listed]
91. Ryder R C, Dunnill M S, Anderson J A. A quantitative study of bronchial mucus gland volume, emphysema and smoking in a necropsy population. J Pathol 1971; 104: 481-487.
92. Anthonisen N R, Connett J E, Enright P L, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
93. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117 (Suppl 2): 398S-401S. [Review]
94. Monto A S, Higgins M W, Ross H W. The Tecumseh Study of Respiratory Illness. VIII. Acute infection in chronic respiratory disease and comparison groups. Am Rev Respir Dis 1975; 111: 27-36.
95. Smith C B, Golden C A, Canner R E, Renzetti A D. Association of viral and mycoplasmal pneumonia infections with acute respiratory illness in patients with COPD. Am Rev Respir Dis 1980; 121: 225-232.
96. Seemungle T S, Harper-Owen R, Bhowmic A, et al. Symptoms, inflammatory markers and respiratory viruses in acute exacerbations and stable COPD. Am J Resp Crit Care Med 2001; 164: 1618-1623.
97. Anthonisen N R, Manfreda J, Warren C P, Hershfield E S, Harding G K, Nelson N A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
98. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-364.
99. Donaldson G C, Seemungal T A R, Bhomik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
100. 1 decline in patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2003; 167: 1090-1095.
101. Kessler R, Faller M, Weitzenblum E, et al. 'Natural history' of pulmonary hypertension in a series of 131 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 219-224.
102. Hale K A, Ewing S L, Goxnell B A, et al. Lung disease in long-term cigarette smokers with and without chronic air-flow obstruction. Am Rev Respir Dis 1984; 130: 716-721.
103. Barbera J A, Peinado V I, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.